BSETAVEXIA LIFECARE LIMITED· RetailingHighNeutral
Announced Mon, 12 Oct, 2026 · 15:16 IST

Tavexia Lifecare to acquire 60% stake in Meyonex Pharma for Rs 67.19 Cr

Listed Co AcquisitionStrategic Transactions View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.7%Reaction day
₹1.20
prior close
₹1.20
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.8%-2.5% vs market
Retailing peers, median of 57sector · industry level+0.0%-1.7% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 1.7 pts less than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.7
10m
-1.7
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.7+0.8-2.5+0.0-1.7
Next day
-1.7+1.0-2.7-0.4-1.2
2d
-2.5+1.7-4.2-0.1-2.4
3d
-3.3+0.1-3.4-0.8-2.5
4d
-2.5+0.8-3.3-0.5-2.0
5d
-1.7-0.9-0.8-1.3-0.3
1w
-3.3-4.5+1.1-5.6+2.3
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 57Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tavexia Lifecare Limited (formerly Sattva Sukun Lifecare, BSE: 539519) will acquire a 60% controlling stake in Meyonex Pharmaceuticals Limited for Rs 67.19 Crore via cash subscription of 2.09 crore fresh shares at Rs 32 each. Meyonex operates manufacturing at MIDC Tarapur, Maharashtra. The company also widened its Main Object Clause to enter APIs, formulations, CDMO/CRAMS, nutraceuticals and biotech. Fund-raising through equity or convertible instruments is planned to finance the expansion.

Likely market impact

Signals a major strategic pivot into pharma manufacturing. Watch for fund-raising announcement that could dilute short-term, but adds long-term growth runway.